CDT Equity Inc.

Overview

Compare with another stock.

• TickerCDT on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersNaples, Florida¹
• Incorporated inDE²
• Business address4851 Tamiami Trail North, Suite 200, Naples, Fl 34103²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Sarborg’s insights have directly informed two new combination patent filings, strengthening our intellectual property portfolio.³ From its latest annual report

Corporate structure

CDT Equity Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CDT Equity Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We currently operate as a virtual company, but also lease property in the United Kingdom. On March 7, 2024, we entered into a lease for laboratory space at Cambridge Science Park. Rent is £92,925 per annum, the equivalent of approximately $10,000 per month. The lease runs until January of 2027, and the laboratory space is intended to provide us with the ability to extend or develop proprietary solid-form intellectual property for existing and future clinical assets.

Item 2 of the 10-K filed Apr 15, 2026.³

Leadership

Who has led CDT Equity Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerAndrew Regan Jun 13, 2025 to now¹⁰
• Chief executive officerDavid Tapolczay Sep 26, 2023 to Nov 20, 2024¹¹
• Chief executive officerJack Kendrick Heilbron Feb 11, 2022 to Feb 11, 2022¹²
• ChairJack Kendrick Heilbron Feb 11, 2022 to Feb 11, 2022¹²
• PresidentJack Kendrick Heilbron Feb 11, 2022 to Feb 11, 2022¹²
• Chief financial officerJames Bligh Jun 11, 2024 to now¹³
• Chief financial officerAdam Sragovicz Feb 11, 2022 to May 15, 2024¹⁴

Former names

• CONDUIT PHARMACEUTICALS INC.Mar 1, 2023 to Aug 7, 2025²
• Murphy Canyon Acquisition Corp.Dec 9, 2021 to Sep 21, 2023²

Timeline

1. Oct 13, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁶
2. Sep 25, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure²⁷
3. Sep 18, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁸
4. Sep 4, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁹
5. Sep 1, 20268-K Executive or director change; Shareholder vote³⁰
6. Sep 1, 20268-K Other events³¹
7. Aug 21, 20268-K Completed an acquisition or sale³²
8. Aug 21, 20268-K Financial statements and exhibits³³
9. Aug 6, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁴
10. Aug 3, 20268-K Completed an acquisition or sale³⁵
11. Jul 31, 20268-K Entered a material agreement; Unregistered sale of shares³⁶
12. Jul 29, 20268-K Unregistered sale of shares³⁷
13. Jun 13, 2025New chief executive Andrew Regan becomes CEO¹⁰
14. Sep 26, 2023New chief executive David Tapolczay becomes CEO¹¹
15. Feb 11, 2022New chief executive Jack Kendrick Heilbron becomes CEO¹²

Calendar

Coming up

1. Nov 12, 2026Reports results for the quarter ending Sep/2026³⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

357 filings to the SEC since October 2021: 5 annual reports, 18 quarterly reports, 78 major events, 64 insider forms, 47 large holders, 145 other. The latest 20:

1. Oct 13, 2026424B3 EDGAR
2. Oct 13, 20268-K EDGAR
3. Oct 8, 2026SCHEDULE 13G/A EDGAR
4. Oct 7, 2026SCHEDULE 13G EDGAR
5. Oct 7, 2026SCHEDULE 13G/A EDGAR
6. Oct 7, 2026SCHEDULE 13G/A EDGAR
7. Oct 2, 2026424B3 EDGAR
8. Sep 25, 20268-K EDGAR
9. Sep 18, 2026424B3 EDGAR
10. Sep 18, 20268-K EDGAR
11. Sep 18, 2026424B3 EDGAR
12. Sep 17, 2026EFFECT EDGAR
13. Sep 9, 2026SCHEDULE 13G EDGAR
14. Sep 8, 2026S-1 EDGAR
15. Sep 4, 20268-K EDGAR
16. Sep 2, 2026SCHEDULE 13G EDGAR
17. Sep 2, 20264 EDGAR
18. Sep 2, 2026SCHEDULE 13D/A EDGAR
19. Sep 1, 20268-K EDGAR
20. Sep 1, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 0 buys and 17 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Primary Development Fund (Cayman) SPC - E3 Fund SPSCHEDULE 13G/A, 4 filings Aug 21, 2026 to Oct 8, 2026³⁹
• Craig Stuart WigglesworthSCHEDULE 13G/A, 2 filings Sep 9, 2026 to Oct 7, 2026⁴⁰
• Mark Andrew TaylorSCHEDULE 13G/A, 4 filings Mar 30, 2026 to Oct 7, 2026⁴¹
• Corvus Capital Ltd.SCHEDULE 13D/A, 7 filings Sep 29, 2023 to Sep 2, 2026⁴²
• Ascent Partners Fund LLCSCHEDULE 13G, 2 filings Feb 18, 2026 to Jun 5, 2026⁴³
• Nirland LtdSCHEDULE 13G, 7 filings Oct 2, 2023 to May 20, 2026⁴⁴
• Sarborg LtdSCHEDULE 13G/A, 2 filings May 7, 2025 to Aug 18, 2025⁴⁵
• A.G.P. / ALLIANCE GLOBAL PARTNERS, LLCSCHEDULE 13G, 1 filing May 15, 2025⁴⁶
• AstraZenecaSCHEDULE 13G/A, 2 filings Oct 11, 2024 to Apr 10, 2025⁴⁷
• St George Street CapitalSC 13G/A, 2 filings Sep 29, 2023 to Nov 6, 2024⁴⁸
• Polar Asset Management Partners Inc.SC 13G/A, 2 filings Feb 10, 2023 to Feb 12, 2024⁴⁹
• Saba Capital Management, L.P.SC 13G/A, 2 filings Feb 11, 2022 to Feb 8, 2024⁵⁰
• Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 10, 2023 to Feb 2, 2024⁵¹
• Murphy Canyon Acquisition Sponsor, LLCSC 13D/A, 3 filings Feb 14, 2022 to Sep 29, 2023⁵²
• Shaolin Capital Management LLCSC 13D, 1 filing Feb 16, 2023⁵³
• MMCAP International Inc. SPCSC 13G/A, 2 filings Feb 10, 2022 to Feb 14, 2023⁵⁴
• Space Summit Capital LLCSC 13G/A, 2 filings Feb 4, 2022 to Feb 8, 2023⁵⁵

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How CDT Equity Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCDT Equity Inc.¹
• CIK0001896212
• Employer ID (EIN)87-3272543³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address4851 Tamiami Trail North, Suite 200, Naples, FL 34103¹
• Phone(646) 491 9132¹
• Shares outstanding786,670 as of Aug 12, 2026⁸
• Public float$55.2K as of Jun 30, 2025³
• AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceDec 9, 2021¹
• Filings357 in all: 8-K (72), 4 (45), CORRESP (21), 3 (19), 424B3 (18), UPLOAD (15), 10-Q (14), EFFECT (13)¹
  All 42 form types

  SCHEDULE 13G (11), 425 (10), SC 13G/A (9), 424B5 (8), SC 13G (8), DEF 14A (7), S-3 (7), 8-K/A (6), PRE 14A (6), SCHEDULE 13D/A (6), SCHEDULE 13G/A (6), 10-K (5), S-8 (5), 10-Q/A (4), S-1 (4), ARS (3), DEFA14A (3), NT 10-Q (3), S-1/A (3), S-4/A (3), SC 13D (3), SC 13D/A (3), 8-A12B (2), CERT (2), DRS (2), NT 10-K (2), SEC STAFF LETTER (2), 25-NSE (1), POS AM (1), RW (1), RW WD (1), S-4 (1), S-8 POS (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Apr 15, 2026
  Quarterly report (10-Q) Aug 12, 2026
  Proxy statement (DEF 14A) Aug 11, 2026
  Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks CDT Equity Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 46 risks under these headings, as written.³

• Risks Related to Our Business and Industry
• We have incurred significant net losses since our inception and we anticipate future losses and negative cash flow. It is uncertain if or when we will become profitable.
• Our business is dependent on the successful development, regulatory approval, and commercialization of our clinical assets, in particular a glucokinase activator which we believe is active in a range of autoimmune disorders, which we refer to as AZD1656, and a potent, irreversible inhibitor of human Myeloperoxidase that has the potential to treat idiopathic male infertility, which we refer to as AZD5904.
• There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our commercial programs, product development efforts or other operations.
• As a result of our limited operating history, we may not be able to correctly estimate, operating expenses, need for investment capital, or stability of operations, which could lead to cash shortfalls.
• Preclinical drug development for our clinical assets (AZD1656 and AZD5904) is expensive, time-consuming, and uncertain. Our preclinical trials may fail to adequately demonstrate pharmacologic activity in therapeutic areas of interest; cause unintended short- or long-term effects in other bodily systems; or produce unexpected toxicity that may alter or risk benefit assessment.
• We may not be successful in our efforts to use and expand our development platform to build a pipeline of clinical assets.
• Clinical drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and uncertain. Our clinical trials may fail to adequately demonstrate the safety and efficacy of our clinical assets, which could prevent or delay regulatory approval and commercialization.
• We may be unable to obtain regulatory approval for our early-stage clinical assets under applicable regulatory requirements. The FDA and foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit, or deny approval of clinical assets. The delay, limitation, or denial of any regulatory approval would adversely impact commercialization, our potential to generate revenue, our business, and our operating results.
• We have identified material weaknesses in our internal control over financial reporting. If we fail to remedy these weaknesses or maintain an effective system of internal controls, then our ability to produce timely and accurate financial statements or comply with applicable regulations could be adversely affected. We may identify additional material weaknesses in our internal controls over financing reporting which we may not be able to remedy in a timely manner.
• There is a risk that we will fail to maintain an effective system of internal controls and our ability to produce timely and accurate financial statements or comply with applicable regulations could be adversely affected. We may identify material weaknesses in our internal controls over financing reporting which we may not be able to remedy in a timely manner.
• If we do not develop and implement all required accounting practices and policies, we may be unable to provide the financial information required of a U.S. publicly traded company in a timely and reliable manner.

Legal proceedings

In August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited (“CPL”), received a letter from Strand Hanson Limited (“Strand”) claiming it was owed advisory fees pursuant to a previously executed letter. CDT rejected and disputes the substance of the letter in full. Following such rejection, on September 7, 2023, Strand filed a claim in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of $2 million and, as a result of the completion of the Business Combination, to be issued 21 shares of common stock. In 2024, the Company offered a $0.4 million settlement to Strand Hanson to avoid expensive litigation, thereby booking an estimated liability of $0.4 million in the accompanying financial statements. On December 8, 2025, the Company and Corvus Capital Limited (“Corvus”) entered into a Sale and Purchase Agreement (the “Agreement”) for the issuance of all of the outstanding shares of CPL held of record by the Company to Corvus. The Company sold CPL, including the potential liability associated with the litigation, to Corvus, a wholly-owned subsidiary of the Company’s Chief Executive Officer for a settlement amount of $7 million that was satisfied through the issuance of shares and pre-funded warrants. On or about January 13, February 20, 2026 and March 4, 2026, CDT received correspondence from Strand, in which, Strand seeks to recover from CDT a judgment it obtained against CPL from the High Court of England and Wales on December 16, 2025 (the “Judgment”), in the amount of approximately $7 million, plus interest and repayment of a fraction of Strand’s costs. CDT denies any and all liability.

The opening of Item 3, Legal Proceedings.³